Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active component of Myfortic, selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the synthesis of guanosine nucleot — a building block required for DNA replication in T‑ and B‑lymphocytes — thereby reducing their proliferation and suppressing immune‑mediated graft rejection.

The dosage of Myfortic is individualized by the prescribing physician based on the type of transplant, patient weight, renal function and concomitant immunosuppressants. Patients should follow the exact regimen provided by their healthcare professional.

Myfortic is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to evidence of fetal harm. It is also not recommended while breastfeeding because the drug can be excreted in milk and may affect the infant.

To order Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolate sodium) is an antimetabolite that specifically targets lymphocyte proliferation, whereas calcineurin inhibitors such as cyclosporine act on T‑cell activation pathways. Myfortic is often combined with calcineurin inhibitors to achieve synergistic immunosuppression while offering a different side‑effect profile.

Myfortic tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Myfortic is taken orally as a delayed‑release tablet, usually with food to improve tolerability. The tablet should be swallowed whole with a full glass of water and not crushed or chewed, as this could affect the controlled‑release properties.

Serious risks include severe neutropenia or agranulocytosis, opportunistic infections (e.g., cytomegalovirus, Pneumocystis jirovecii), hepatic toxicity, and rare but life‑threatening allergic reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection or blood‑cell abnormalities.

Myfortic should not be used by individuals who are pregnant, have known hypersensitivity to mycophenolate sodium or any tablet excipients, or have uncontrolled severe infections. Caution is also advised in patients with significant renal or hepatic impairment.